Livagen
Anti-AgingKEDA — Synthetic Peptide
Overview
Livagen is a synthetic tetrapeptide Lys-Glu-Asp-Ala (KEDA), developed as a liver and immune bioregulator by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology. Despite its classification as a "liver" bioregulator based on its origin from bovine liver tissue extract, the published evidence for Livagen focuses primarily on its effects on chromatin structure in lymphocytes — positioning it more accurately as an immune/epigenetic aging compound.
Mechanism of Action
Livagen belongs to the short peptide DNA-binding bioregulator class (consistent with Khavinson's broader framework). The primary published mechanism is chromatin decondensation: Livagen induces de-heterochromatinization in aged human lymphocytes, specifically targeting pericentromeric heterochromatin regions that become abnormally condensed with cellular aging.
This chromatin reactivation: - Restores access to ribosomal RNA gene loci that are silenced by age-related heterochromatin spreading - Activates expression of genes involved in protein synthesis and immune function - Is proposed to reverse epigenetic silencing that accumulates in the immune cells of elderly individuals
The mechanism is consistent with the broader Khavinson-class hypothesis: short peptides interact directly with DNA regulatory sequences or chromatin structural proteins, modulating gene expression through epigenetic rather than receptor-mediated pathways.
Research Dosing
Dosing from Russian research protocols. Livagen is a short-course bioregulator in the Khavinson tetrapeptide class. Limited safety and efficacy data outside Russian sources. Not approved by FDA or EMA.
Research data only. These dosing ranges are derived from published studies, primarily in animal models. This is not medical advice. No peptide discussed on this site is approved for human therapeutic use unless otherwise noted.